Profile data is unavailable for this security.
About the company
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
- Revenue in USD (TTM)5.62bn
- Net income in USD1.43bn
- Incorporated1999
- Employees19.80k
- LocationEdwards Lifesciences CorpOne Edwards WayIRVINE 92614United StatesUSA
- Phone+1 (949) 250-2500
- Fax+1 (302) 655-5049
- Websitehttps://www.edwards.com
More ▼
Mergers & acquisitions
| Acquired company | EW:NYQ since announced | Transaction value |
|---|---|---|
| JC Medical Inc | 1.40% | -- |
| JenaValve Technology Inc | -19.72% | -- |
| Endotronix Inc | -19.72% | 1.65bn |
| Innovalve Bio Medical Ltd | -23.19% | -- |
Data delayed at least 15 minutes, as of Nov 21 2024 15:24 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Illumina Inc | 4.39bn | -1.58bn | 20.88bn | 10.59k | -- | 9.85 | -- | 4.76 | -10.00 | -10.00 | 27.61 | 13.36 | 0.5441 | 2.66 | 6.17 | 414,542.00 | -19.63 | -6.20 | -23.16 | -7.28 | 63.94 | 66.39 | -36.08 | -15.48 | 1.85 | 38.44 | 0.4834 | -- | -1.75 | 6.21 | 73.64 | -- | -7.91 | -- |
| Steris PLC | 5.12bn | 602.62m | 20.95bn | 18.18k | 34.93 | 3.18 | 18.92 | 4.09 | 6.08 | 4.38 | 51.62 | 66.80 | 0.4758 | 3.86 | 5.49 | 281,655.40 | 5.62 | 5.19 | 6.10 | 5.68 | 43.01 | 43.64 | 11.81 | 10.97 | 1.55 | 8.29 | 0.2528 | 36.56 | 13.28 | 13.06 | -1.07 | 12.67 | 13.69 | 8.83 |
| Waters Corp | 2.91bn | 622.64m | 21.24bn | 7.90k | 34.14 | 13.25 | 26.07 | 7.31 | 10.48 | 10.48 | 48.89 | 27.00 | 0.645 | 2.20 | 4.47 | 367,740.10 | 13.82 | 19.77 | 16.72 | 25.29 | 59.73 | 58.45 | 21.43 | 23.38 | 1.38 | 10.11 | 0.5325 | 0.00 | -0.5229 | 4.09 | -9.26 | 1.53 | 4.72 | -- |
| Zimmer Biomet Holdings Inc | 7.60bn | 1.08bn | 21.75bn | 18.00k | 20.81 | 1.76 | 10.57 | 2.86 | 5.25 | 5.25 | 36.87 | 62.00 | 0.3538 | 0.9136 | 5.38 | 421,972.20 | 5.05 | 2.21 | 5.82 | 2.52 | 71.78 | 71.25 | 14.28 | 7.28 | 0.6987 | 7.52 | 0.3425 | 38.90 | 6.55 | -1.40 | 252.86 | -- | 9.44 | 0.00 |
| West Pharmaceutical Services Inc. | 2.88bn | 499.60m | 22.57bn | 10.60k | 46.18 | 8.21 | 35.59 | 7.85 | 6.75 | 6.75 | 38.86 | 37.96 | 0.7743 | 4.50 | 5.51 | 271,358.50 | 13.02 | 15.61 | 15.16 | 18.65 | 34.87 | 38.06 | 16.81 | 18.47 | 2.23 | -- | 0.0695 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
| DexCom Inc | 3.95bn | 680.80m | 29.39bn | 9.60k | 45.93 | 14.85 | 32.90 | 7.43 | 1.64 | 1.64 | 9.52 | 5.07 | 0.6107 | 2.76 | 4.42 | 411,875.00 | 10.51 | 8.30 | 14.28 | 10.50 | 62.10 | 65.90 | 17.22 | 14.14 | 2.12 | -- | 0.5579 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
| Veeva Systems Inc | 2.57bn | 615.26m | 34.11bn | 7.17k | 54.65 | 6.57 | 52.33 | 13.25 | 3.85 | 3.85 | 15.69 | 32.04 | 0.4453 | -- | 6.27 | 358,846.80 | 10.65 | 11.97 | 12.97 | 15.36 | 73.35 | 72.00 | 23.91 | 23.74 | -- | -- | 0.00 | 0.00 | 9.68 | 22.35 | 7.79 | 18.00 | 21.68 | -- |
| IDEXX Laboratories, Inc. | 3.84bn | 866.24m | 34.28bn | 11.00k | 40.39 | 21.22 | 34.55 | 8.92 | 10.36 | 10.36 | 46.00 | 19.72 | 1.19 | 3.85 | 7.14 | 349,528.80 | 26.91 | 28.00 | 38.86 | 43.49 | 60.72 | 58.74 | 22.53 | 21.35 | 1.03 | 59.10 | 0.3507 | 0.00 | 8.72 | 10.59 | 24.44 | 17.39 | 1.68 | -- |
| Resmed Inc | 4.81bn | 1.11bn | 35.46bn | 9.98k | 32.02 | 6.82 | 27.50 | 7.38 | 7.54 | 7.54 | 32.59 | 35.39 | 0.6886 | 2.17 | 6.08 | 481,711.90 | 15.94 | 14.24 | 18.11 | 16.53 | 57.67 | 56.85 | 23.15 | 20.35 | 1.91 | 44.71 | 0.1154 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.34 |
| Agilent Technologies Inc | 6.50bn | 1.41bn | 36.94bn | 17.40k | 26.74 | 6.26 | 22.21 | 5.69 | 4.81 | 4.81 | 22.14 | 20.53 | 0.5996 | 2.87 | 5.06 | 358,950.30 | 13.04 | 11.00 | 16.13 | 13.25 | 54.75 | 53.29 | 21.75 | 18.01 | 1.37 | 55.86 | 0.3319 | 21.46 | -0.219 | 6.82 | -1.12 | 7.39 | 10.98 | 8.86 |
| GE HealthCare Technologies Inc | 19.56bn | 1.68bn | 38.79bn | 51.00k | 23.25 | 4.66 | 16.77 | 1.98 | 3.65 | 3.65 | 42.63 | 18.20 | 0.5906 | 5.40 | 4.41 | 383,490.20 | 5.22 | -- | 6.97 | -- | 41.33 | -- | 8.84 | -- | 0.982 | 5.67 | 0.5478 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| Edwards Lifesciences Corp | 5.62bn | 1.43bn | 41.01bn | 19.80k | 29.37 | 4.30 | 26.26 | 7.30 | 2.37 | 6.93 | 9.32 | 16.18 | 0.5032 | 1.12 | 7.72 | 283,904.00 | 12.76 | 16.63 | 14.98 | 19.12 | 78.63 | 76.71 | 25.35 | 24.84 | 2.89 | -- | 0.0585 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Cencora Inc | 293.96bn | 1.51bn | 47.92bn | 42.00k | 32.40 | 60.91 | 18.18 | 0.163 | 7.51 | 7.51 | 1,467.70 | 3.99 | 4.53 | 15.59 | 12.44 | -- | 2.34 | 1.12 | 11.51 | 4.83 | 3.35 | 3.25 | 0.5168 | 0.2556 | 0.5291 | 19.37 | 0.848 | 65.38 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
Data as of Nov 21 2024. Currency figures normalised to Edwards Lifesciences Corp's reporting currency: US Dollar USD
34.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 59.93m | 9.95% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 32.85m | 5.45% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 28.89m | 4.80% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 26.27m | 4.36% |
| Geode Capital Management LLCas of 30 Sep 2024 | 13.52m | 2.25% |
| Walter Scott & Partners Ltd.as of 30 Sep 2024 | 12.43m | 2.06% |
| Fisher Asset Management LLCas of 30 Sep 2024 | 9.08m | 1.51% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 8.54m | 1.42% |
| Ninety One UK Ltd.as of 30 Sep 2024 | 7.31m | 1.21% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2024 | 7.05m | 1.17% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
